Introduction
============

Accurate staging and thorough tumour surveillance are essential in patients with a neoplastic disease to assess prognosis and to decide the most appropriate therapeutic options. Imaging plays a key role in these evaluation steps: multi-slice computed tomography (CT) and, recently, positron emission tomography/CT (PET/CT) are widely used in order to get an integrated diagnostic approach to cancer as a systemic disease.[@b1-rado-47-03-206] In particular, the use of Fluorine-18-Fluorodeoxyglucose (FDG) tracer made, up to now, PET contribution to oncologic imaging matchless by any other functional imaging modality.[@b2-rado-47-03-206] However, this technique uses ionizing radiations and has some limitations for what concerns spatial and contrast resolution; false positive and false negative results of FDG-PET are well known, too.

Magnetic resonance imaging (MRI), with its lack of ionizing radiation, high soft tissue contrast and good spatial resolution, is a useful application for tumour detection and staging of malignancies and could overcome the limits of FDG-PET/CT.[@b3-rado-47-03-206]

In recent years, significant improvements in hardware and important innovations in sequence design and image acquisition have allowed a whole-body imaging with MRI in a suitable acquisition time without impairment of spatial resolution.[@b4-rado-47-03-206] Furthermore, the introduction of diffusion-weighted MRI (DWI) has increased the potential for the detection of malignancies throughout the body.[@b5-rado-47-03-206] Whole body MRI (WB-MRI) has then emerged as an excellent candidate for staging and surveillance of patients with neoplastic disease and many authors have compared FDG-PET/CT and WB-MRI in oncology.

Our article aims to systematically review the current evidence on the comparison between PET or PET/CT using FDG and WB-MRI in patients with different tumours.

Methods
=======

A comprehensive literature search of studies published in PubMed/MEDLINE, Scopus and Embase databases was carried out to find relevant peer-reviewed articles on the comparison of FDG-PET or PET/CT and WB-MRI in patients with different tumours.

A search algorithm based on a combination of the terms: a) "PET" OR "positron emission tomography" AND b) "whole body MR" OR "whole-body MR" OR "whole body magnetic resonance" OR "whole-body magnetic resonance" OR "whole body MRI" OR "whole-body MRI" was used. No beginning date limit was used and the search was updated until April 2012.

All the studies which compared FDG-PET or PET/CT and WB-MRI in oncology were considered eligible for inclusion in this systematic review.

The exclusion criteria were: a) articles not within the field of interest of this review; b) review articles, editorials or letters, comments, conference proceedings; c) case reports or small case series (less than seven patients included); d) articles not in English, Spanish, French or German language; e) possible data overlap (in this case the most complete article was included).

Two researchers (MC and GT) reviewed the titles and the abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. The full-text version of the retrieved articles was reviewed to confirm their eligibility for inclusion. Disagreements were resolved in a consensus meeting.

For each included study, information was collected concerning basic study (authors, journal, year of publication, country of origin, type of study), patient characteristics (number of patients, mean age, gender and type of tumours evaluated), methodological aspects about PET imaging (device used, injected activity, time between tracer injection and image acquisition, PET acquisition protocol, image analysis), methodological aspects about WB-MRI (field strength, sequences used, slice thickness, contrast media, diffusion-weighted imaging, apparent diffusion coefficient, acquisition time) and reference standard used.

Results
=======

Literature search
-----------------

The comprehensive literature search revealed 688 articles. Reviewing titles and abstracts, 644 articles were excluded applying the criteria mentioned above: 564 studies were excluded because not within the range of interest of this review; 69 articles were excluded because review articles, editorials or letters, comments, conference proceedings; 4 articles were excluded because case reports or small case series (less than seven patients included)[@b6-rado-47-03-206]--[@b9-rado-47-03-206]; 2 articles were excluded because not in English, Spanish, French or German language[@b10-rado-47-03-206],[@b11-rado-47-03-206]; 5 articles were excluded for possible data overlap.[@b12-rado-47-03-206]--[@b16-rado-47-03-206]

Lastly, forty-four articles comprising 2287 patients were retrieved in full-text version and included in this systematic review ([Figure 1](#f1-rado-47-03-206){ref-type="fig"}).[@b17-rado-47-03-206]--[@b60-rado-47-03-206] No additional studies were found screening the references of these articles.[@b6-rado-47-03-206]--[@b16-rado-47-03-206] The characteristics of the included studies are presented in [Tables 1](#t1-rado-47-03-206){ref-type="table"}--[3](#t3-rado-47-03-206){ref-type="table"}.

Mixed tumours were evaluated in 12 articles[@b17-rado-47-03-206]--[@b28-rado-47-03-206], lymphomas in 7[@b29-rado-47-03-206]--[@b35-rado-47-03-206]; bone tumours in 7[@b36-rado-47-03-206]--[@b42-rado-47-03-206]; head and neck tumours in 5[@b43-rado-47-03-206]--[@b47-rado-47-03-206]; lung tumours in 4[@b48-rado-47-03-206]--[@b51-rado-47-03-206]; melanoma in 3[@b52-rado-47-03-206]--[@b54-rado-47-03-206]; breast cancer in 2[@b55-rado-47-03-206],[@b56-rado-47-03-206]; colorectal tumours in 2[@b57-rado-47-03-206],[@b58-rado-47-03-206]; neuroendocrine tumours in 2.[@b59-rado-47-03-206],[@b60-rado-47-03-206]

Literature data discussion
--------------------------

### Mixed tumours

First of all, Antoch *et al*.[@b17-rado-47-03-206] performing both FDG-PET/CT and WB-MRI in 98 patients with different malignancies, recommended the use of FDG-PET/CT as first-line whole-body imaging modality for tumour staging. In fact, the overall TNM stage was correctly determined in 75 cases with PET/CT (77%) and in 53 with WB-MRI (54%). Compared with WB-MRI, PET/CT had a direct impact on patient management in 12 patients. WB-MRI findings changed the therapy regimen in 2 patients compared with PET/CT.[@b17-rado-47-03-206]

In 2005, Schmidt *et al*.[@b18-rado-47-03-206] evaluating 41 patients with mixed tumours using both methods found that WB-MRI was highly sensitive in detecting distant metastases (sensitivity was 96% for WB-MRI and 82% for FDG-PET/CT; specificity was 82% for both methods), whereas PET/CT was superior in lymph node staging (sensitivity was 98% for PET/CT and 80% for WB-MRI; specificity was 83% for PET/CT and 75% for WB-MRI). Accuracy for correct TNM staging was 96% for PET/CT and 91% for WB-MRI.[@b18-rado-47-03-206]

In 2007 Komori *et al*.[@b19-rado-47-03-206] comparing FDG-PET/CT and DWI WB-MRI in 16 patients with malignant tumours reported that DWI WB-MRI may be useful in detecting malignancies, even if differentiating malignant and benign tumours may be difficult with this method. Twenty-five (92.6%) of the 27 malignant lesions were detected by DWI WBMRI whereas 22 malignant tumours (81.5%) were detected by FDG-PET/CT.[@b19-rado-47-03-206]

Also Li *et al*.[@b20-rado-47-03-206] reported that DWI WB-MRI is a feasible imaging method in oncology, providing comparable results to PET imaging in 30 oncologic patients evaluated.

Brauck *et al*.[@b21-rado-47-03-206] evaluated a WB-MRI protocol by using unenhanced T2-weighted and contrast-enhanced T1-weighted real-time sequences during continuous table movement in 11 patients with FDG-PET/CT positive for metastases. Seventy-three of 75 metastases detected by PET/CT were correctly diagnosed by using WB-MRI, demonstrating the feasibility of this method in detecting metastases.[@b21-rado-47-03-206]

In 2008, Yang *et al*.[@b22-rado-47-03-206] evaluated 56 patients with different tumours demonstrating the valuable role of DWI WB-MRI in tumour detection. Twelve patients underwent also FDG-PET. Among the diagnostic imaging methods DWI WB-MRI showed the highest sensitivity and specificity in detecting bone metastases. Among the twelve results compared with PET, eight were identical (concordance of 66.7%), one was found to be false-positive at MRI, two were found false-negative at MRI, one case was false-negative at PET and true-positive at MRI.[@b22-rado-47-03-206]

In 2009, Stecco *et al*.[@b23-rado-47-03-206] compared FDG-PET/CT and DWI WB-MRI in staging 29 oncologic patients. Using FDG-PET/CT as reference standard, DWI WB-MRI interpreted by two readers had a sensitivity of 87--89%, a specificity of 98--99%, and an accuracy of 98--99%. These authors underlined the usefulness of DWI WB-MRI in cancer screening, staging, restaging and follow-up.[@b23-rado-47-03-206]

Krohmer *et al*.[@b24-rado-47-03-206] evaluated 24 paediatric tumours with WB-MRI and FDG-PET, showing that WBMRI had high sensitivity for the detection of malignant disease. Overall 190 lesions were detected by WB-MRI and 155 lesions were found by FDG-PET. In patients with suspected bone lesions, WB-MRI should be considered for initial disease evaluation prior to specific and regional imaging methods to reduce the overall number of imaging examinations and radiation exposure.[@b24-rado-47-03-206]

In 2011, Fischer *et al*.[@b25-rado-47-03-206] prospectively evaluated the diagnostic accuracy of WB-MRI with and without DWI compared with PET/CT (as reference standard) in 66 oncologic patients. PET/CT revealed 374 malignant lesions in 48/64 (75%) patients. Detection rates of WB-MRI with and without DWI were 84% and 64%, respectively. The detection rate was significantly higher with side-by-side analysis and fused image analysis compared with WB-MRI alone.[@b25-rado-47-03-206]

Recently, Schmidt *et al*.[@b26-rado-47-03-206] demonstrated that both FDG-PET/CT and WB-MRI were efficient diagnostic triage methods in 135 patients planned for radioembolisation of liver metastases. Overall, FDG-PET/CT showed a higher diagnostic accuracy compared to WB-MRI. Both modalities, combined, exhibited high sensitivity for the diagnosis of extra-hepatic tumour manifestations. Patient-based sensitivity for detection of extra-hepatic disease was 94% for PET/CT and 91% for WB-MRI. Overall, by combining both modalities, the specificity for inclusion to radioembolisation therapy was 99%.[@b26-rado-47-03-206]

Cafagna *et al*.[@b27-rado-47-03-206] evaluating 38 cancer patients demonstrated that DWI WB-MRI may be used in detecting tumours but is less effective in characterizing lymph nodal and bone lesions compared to FDG-PET/CT. The qualitative analysis of DWI WB-MRI and FDG-PET/CT showed that two patients were negative at both techniques. DWI WB-MRI was positive in 36 patients, 34 of whom were positive and two negative at FDG-PET/CT, respectively. A significant discordance was found between the two methods (255 lesions were identified by DWI WB-MRI and 184 by FDG-PET/CT).[@b27-rado-47-03-206]

Lastly, Manenti *et al*.[@b28-rado-47-03-206] reported that DWI WB-MRI should be considered as alternative tool to conventional whole-body methods for tumour staging in cancer patients. Evaluating 45 patients using both methods, detection rates of malignancy did not differ between DWI WB-MRI and FDG-PET/CT.[@b28-rado-47-03-206]

### Lymphomas

#### Staging

Punwani *et al*.[@b29-rado-47-03-206] evaluated 31 subjects with lymphoma using both WB-MRI and enhanced FDG-PET/CT (used as reference standard) demonstrating that WB-MRI can accurately depict nodal and extranodal disease and may provide an alternative non-ionizing imaging method for initial staging. WB-MRI and enhanced PET/CT showed a good agreement for nodal and extranodal staging. The sensitivity and specificity of WB-MRI were 98% and 99%, respectively, for nodal disease; 91% and 99%, respectively, for extranodal disease.[@b29-rado-47-03-206]

van Ufford *et al*.[@b30-rado-47-03-206] compared DWI WB-MRI with FDG-PET/CT in the staging of 22 patients with newly diagnosed lymphoma. These authors found a moderate overall agreement between DWI WB-MRI and FDG-PET/CT. Ann Arbor staging, according to DWI WB-MRI findings, was concordant with that of FDG PET/CT findings in 77% (17/22) of patients. In the care of patients with newly diagnosed lymphoma, staging with DWI WB-MRI did not result in underestimation of stage relative to the results with FDG-PET/CT. In a minority of patients, reliance on DWI WB-MRI led to clinically important overstaging relative to the results with FDG-PET/CT.[@b30-rado-47-03-206]

Recently, Abdulqadhr *et al*.[@b31-rado-47-03-206] compared DWI WB-MRI with FDG-PET/CT in the staging of 31 lymphoma patients (8 with Hodgkin's lymphoma and 23 with non-Hodgkin's lymphomas). The staging was the same for DWI WB-MRI and FDG-PET/CT in 28 (90.3%) patients and different in three (9.7%). No Hodgkin lymphoma or aggressive non-Hodgkin's lymphoma patients had different staging using both methods. Three indolent lymphocytic lymphomas had higher staging with DWI WB-MRI when compared with FDG-PET/CT.[@b31-rado-47-03-206]

Gu *et al*.[@b32-rado-47-03-206] evaluated the diagnostic performance of WB-MRI with or without DWI in the detection of 17 patients with newly diagnosed lymphomas, using FDG-PET/CT as the reference standard. The addition of DWI to conventional WB-MRI improved diagnostic accuracy for lymphomas. These authors suggested that WB-MRI could be useful as an alternative method to FDG-PET/CT in the management of lymphomas.[@b32-rado-47-03-206]

#### Treatment response assessment

Lin *et al*.[@b33-rado-47-03-206] assessed post-treatment changes in 15 patients with diffuse large B-cell lymphomas on DWI WB-MRI using PET/CT as the reference standard. After chemotherapy, among 85 examined lymph nodal regions, residual nodes were present in 62 (73%) regions on DWI WB-MRI. Of these 62 regions, 26 had persistent lymph nodes with longest transverse diameter \> 10mm (MRI size criteria for positivity). Only 6 of these 26 regions were considered positive on PET/CT. DWI with ADC mapping showed a significant increase in ADC values of residual masses persisting after treatment and were helpful to assess the treatment response in patients with diffuse large B-cell lymphomas.[@b33-rado-47-03-206]

Wu *et al*.[@b34-rado-47-03-206] evaluated the feasibility of DWI WB-MRI in the early chemotherapeutic response assessment of 8 patients with large B-cell lymphomas. These authors found that the results of WB-MRI with or without DWI were comparable with those of FDG-PET/CT.[@b34-rado-47-03-206]

Recently, Chen *et al*.[@b35-rado-47-03-206] reported that DWI WB-MRI, combined with the dynamic changes of ADC value, was a valid alternative method compared to FDG PET/CT in assessing treatment response to chemotherapy in 10 patients with non-Hodgkin's lymphoma.[@b35-rado-47-03-206]

### Bone tumours

#### Primary tumours

Shortt *et al*.[@b36-rado-47-03-206] found that WB-MRI performed better than FDG-PET/CT in the assessment of disease activity in 24 patients with multiple myeloma. FDG-PET/CT had a sensitivity of 59%, specificity of 75%, and accuracy of 65%. WB-MRI had a sensitivity of 68%, specificity of 83% and accuracy of 74%. In 62% of cases, FDG-PET/CT and WB-MRI findings were concordant. When PET and WB-MRI findings were concordant and positive, specificity was 100%.[@b36-rado-47-03-206]

#### Bone metastases

Daldrup-Link *et al*.[@b37-rado-47-03-206] compared the diagnostic accuracy of WB-MRI and FDG-PET for the detection of bone metastases in 39 children. Sensitivity for the detection of bone metastases were 90% for FDG-PET and 82% for WB-MRI.[@b37-rado-47-03-206]

In 2007, Schmidt *et al*.[@b38-rado-47-03-206] prospectively compared the diagnostic accuracy of WB-MRI and FDG-PET/CT for the detection of bone metastases in 30 patients with different oncologic diseases. WB-MRI showed a sensitivity, specificity and accuracy of 94%, 76% and 91%, respectively. PET/CT achieved a sensitivity, specificity and accuracy of 78%, 80% and 78%, respectively. Cut-off size for the detection of malignant bone lesions was 2 mm for WB-MRI and 5 mm for PET/CT.[@b38-rado-47-03-206]

In 2008, Ribrag *et al*.[@b39-rado-47-03-206] suggested that non-invasive morphological procedures (WB-MRI and FDG-PET/CT) could be superior to bone marrow biopsy for bone marrow assessment in aggressive lymphomas. Both WB-MRI and PET/CT detected bone marrow lesions in the 9/43 patients, but two patients with multiple lesions had more lesions detected by PET/CT compared to MRI.[@b39-rado-47-03-206]

Kumar *et al*.[@b40-rado-47-03-206] compared WB-MRI and FDG-PET/CT for the detection of bone marrow metastases in 26 children with small-cell neoplasms. WB-MRI showed a sensitivity, specificity and accuracy of 97.5%, 99.4%, and 99% respectively. FDG-PET/CT showed a sensitivity, specificity and accuracy of 90.0%, 100%, and 98%. Both WB-MRI and FDG-PET/CT showed excellent agreement with the final diagnosis.[@b40-rado-47-03-206]

In 2009, Takenaka *et al*.[@b41-rado-47-03-206] prospectively compared WB-MRI (with and without DWI) and FDG-PET/CT in the detection of bone metastases in 115 patients with non-small cell lung cancer. These authors suggested that DWI WB-MRI can be used for bone metastases assessment in patients with non-small cell lung cancer being more accurate than bone scintigraphy and FDG-PET/CT.[@b41-rado-47-03-206]

Recently, Heusner *et al*.[@b42-rado-47-03-206] found that FDG-PET/CT and WB-MRI were equally suitable for the detection of bone metastases in 109 patients with non-small cell lung cancer and malignant melanoma. The sensitivity, specificity, and accuracy for the detection of bone metastases was 45%, 99%, and 94% with FDG-PET/CT and 64%, 94%, and 91% with WB-MRI.[@b42-rado-47-03-206]

### Head and neck tumours

In 2010, Ng *et al*.[@b43-rado-47-03-206] prospectively compared WB-MRI and FDG-PET/CT for the detection of residual/recurrent nasopharyngeal carcinoma in 179 patients. On a per patient-based analysis, sensitivity and specificity of WB-MRI were similar to those of FDG-PET/CT (90.9% *vs*. 87.3%, and 91.1% vs. 90.3%, respectively). A combined interpretation of both methods increased the sensitivity to 94.5%.[@b43-rado-47-03-206]

In the same year, O'Neill *et al*.[@b44-rado-47-03-206] compared WB-MRI and FDG-PET/CT for the staging of 15 patients with head and neck tumours. This study found radiological staging discordance between the two imaging modalities: T-staging showed a 74% of concordance, N-staging a 80% of concordance and M-stage a 100% of concordance.[@b44-rado-47-03-206]

Recently, Ng *et al*.[@b45-rado-47-03-206] compared WB-MRI and FDG-PET/CT in 79 treated oropharyngeal or hypopharyngeal squamous cell carcinoma. PET/CT showed a trend towards higher diagnostic accuracy than WB-MRI in detecting residual/recurrent tumours or second primary tumours. The combined use of PET/CT and WB-MRI provided more added value to WB-MRI alone than to PET/CT alone. Sensitivity and specificity of FDG-PET/CT on a patient-based analysis were 72% and 94%. Sensitivity and specificity of WB-MRI on a patient-based analysis were 55% and 90%.[@b45-rado-47-03-206]

The same group prospectively compared the diagnostic value of FDG-PET/CT and WB-MRI for the assessment of distant metastases and second primary cancers in 103 patients with untreated oropharyngeal or hypopharyngeal squamous cell carcinoma. Again, FDG-PET/CT showed a consistent trend toward higher sensitivity compared to WB-MRI for the detection of distant metastases and secondary primary cancers in these patients.[@b46-rado-47-03-206]

Lastly, Eiber *et al*.[@b47-rado-47-03-206] reported that a combination of FDG-PET/CT and WB-MRI increased the diagnostic accuracy in the staging of 20 patients with head and neck tumours.[@b47-rado-47-03-206]

### Lung cancer

In 2008, Plathow *et al*.[@b48-rado-47-03-206] evaluated and compared FDG-PET/CT with WB-MRI in the correct staging of 52 patients with advanced non-small cell lung cancer (NSCLC). In the correct staging of advanced NSCLC, PET/CT had advantages in N-staging, whereas WB-MRI had certain advantages in T-staging. WB-MRI correctly T-staged all patients. PET/CT did not correctly stage chest wall infiltration in 4 cases (sensitivity: 92.3%; specificity: 100%). PET/CT correctly N-staged 51 patients (sensitivity: 96.1%; specificity: 100%). WB-MRI showed a significant tendency to understage N-status (sensitivity: 88.5%; specificity: 96.1%). In 2 patients, distant metastases were detected by both techniques.[@b48-rado-47-03-206]

In the same year, Ohno *et al*.[@b49-rado-47-03-206] prospectively compared WB-MRI with and without DWI and FDG-PET/CT for M-stage assessment in 203 NSCLC patients. These authors found that DWI WB-MRI can be used for M-stage assessment in NSCLC patients with accuracy as good as that of PET/CT. The area under the ROC curve was 0.89 for FDG-PET/CT, 0.85 for DWI WB-MRI and 0.81 for WB-MRI without DWI, excluding brain metastases (due to the low accuracy of FDG-PET/CT in detecting brain metastases).[@b49-rado-47-03-206]

Yi *et al*.[@b51-rado-47-03-206] prospectively compared the diagnostic accuracy of FDG-PET/CT and WB-MRI for TNM stage of 165 patients with NSCLC. WB-MRI was more useful for detecting brain and hepatic metastases, whereas PET/CT was more useful for detecting lymph node and soft-tissue metastases. Primary tumours (n=123 patients) were correctly staged in 101 (82%) patients at PET/CT and in 106 (86%) patients at WB-MRI. N stages (n=150 patients) were correctly determined in 105 (70%) patients at PET/CT and in 102 (68%) patients at WB-MRI. Thirty-one (20%) of 154 patients had metastatic lesions. Accuracy for detecting metastases was comparable between PET/CT and WB-MRI (86%). WB-MRI was more useful for detecting brain and hepatic metastases, whereas PET/CT was more useful for detecting lymph node and soft-tissue metastases.[@b50-rado-47-03-206]

Chen *et al*.[@b51-rado-47-03-206] compared the diagnostic accuracy of DWI WB-MRI and FDG-PET/CT for assessment of 56 NSCLC patients. DWI WB-MRI was a feasible imaging method for the assessment of lymph nodal and metastatic spread with high accuracy, but it was limited in the evaluation of neck lymph nodal metastases and small metastatic lung nodules. Primary tumours were correctly detected in 56 (100%) patients by both PET/CT and DWI WB-MRI. Sensitivity, specificity and accuracy for lymph nodal metastases were 91%, 90% and 90% with DWI WB-MRI and 98%, 97% and 97% with PET/CT, respectively. Sensitivity, specificity and accuracy for other metastases were 90%, 95% and 92% with DWI WB-MRI and 98%, 100% and 98% with PET/CT.[@b51-rado-47-03-206]

### Melanoma

Pfannenberg *et al*.[@b52-rado-47-03-206] compared the diagnostic accuracy and impact on patient management of FDG-PET/CT and WB-MRI in staging of 64 patients with advanced melanoma. The overall accuracy of PET/CT was 86.7% compared to 78.8% for WB-MRI. PET/CT was significantly more accurate in N-staging and in detecting skin and subcutaneous metastases, whereas WB-MRI was more sensitive in detecting liver, bone and brain metastases. WB-MRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions.[@b52-rado-47-03-206]

Laurent *et al*.[@b53-rado-47-03-206] compared WB-MRI (with and without DWI) and FDG-PET/CT for staging of 35 patients with advanced melanoma. The sensitivity and specificity for WB-MRI without DWI were 82% and 97%, respectively, while for PET/CT were 72.8% and 92.7%, respectively. DWI allowed the detection of 14 supplementary malignant lesions (20%) in comparison with standard MRI protocol.[@b51-rado-47-03-206] In particular WB-MRI has been shown to be the most accurate method for detecting metastases in the liver, bone, subcutaneous and intra-peritoneal sites.[@b53-rado-47-03-206]

Recently, Dellestable *et al*.[@b54-rado-47-03-206] found that DWI WB-MRI was superior compared to FDG-PET/CT in the staging of 40 patients with melanoma. Sensitivity and specificity were 74% and 89% for FDG-PET/CT, 83% and 96% for DWI WB-MRI. The sensitivity of MRI was distinctly superior compared to that of PET/CT for both hepatic and pulmonary lesions.[@b54-rado-47-03-206]

### Breast cancer

Schmidt *et al*.[@b55-rado-47-03-206] compared the diagnostic accuracy of WB-MRI and FDG-PET/CT for the detection of tumour recurrence in 33 patients with breast cancer. WB-MRI and PET/CT were both useful for the detection of tumour recurrence. WB-MRI was highly sensitive to detect distant metastatic disease. PET/CT was more sensitive in detecting lymph node involvement. Overall sensitivity was 91% for PET/CT and 90% for WB-MRI. Overall specificity was 90% for FDG-PET/CT and 86% for WB-MRI.[@b55-rado-47-03-206]

Heusner *et al*.[@b56-rado-47-03-206] prospectively compared the diagnostic value of DWI WB-MRI and FDG-PET/CT for breast cancer staging in 20 patients. DWI resulted a sensitive but unspecific method for the detection of locoregional or metastatic breast cancer. These authors suggested that DWI WB-MRI is not alternative to FDG-PET/CT in staging breast cancer. The sensitivity, specificity, and accuracy for FDG-PET/CT were 94%, 99%, and 98%, respectively, whereas for DWI WB-MRI were 91%, 72%, and 76%, respectively.[@b56-rado-47-03-206]

### Colorectal cancer

Squillaci *et al*.[@b57-rado-47-03-206] assessed the accuracy of WB-MRI in comparison with FDG-PET/CT in staging 20 patients with colorectal carcinoma. These authors found that WB-MRI was a feasible method for staging colorectal cancer but could not substitute PET/CT. Lymph-nodal metastases were detected in 10/20 cases at WB-MRI and in 15/20 at PET/CT. M-stage was evaluated for liver metastases (27 lesions detected in 15 patients with WB/MRI; 23 lesions detected in 15 patients with PET/CT), lung metastases (19 lesions detected in 5 patients with WB-MRI, 25 lesions detected in 7 patients with PET/CT), and bone (9 lesions detected in 3 patients with both methods).[@b57-rado-47-03-206]

Schmidt *et al*.[@b58-rado-47-03-206] assessed the diagnostic accuracy of WB-MRI compared with FDG-PET/CT in the follow-up of 24 patients suffering from colorectal cancer. Malignant foci were detected in 71% of patients with both methods. Lymph nodal metastases were better detected using PET/CT (sensitivity was 93% for PET/CT and 63% for WB-MRI), whereas distant metastases were depicted equally well by both investigations (sensitivity was 80% for PET/CT and 78% for WB-MRI). Overall sensitivity, specificity and diagnostic accuracy was 86%, 96% and 91% for PET/CT, and 72%, 93% and 83% for WB-MRI.[@b58-rado-47-03-206]

### Neuroendocrine tumours

Giraudet *et al*.[@b59-rado-47-03-206] comparing FDG-PET/CT and WB-MRI in 50 patients with suspected recurrent medullary thyroid carcinoma found a superior diagnostic accuracy of WB-MRI compared to FDG-PET/CT.[@b59-rado-47-03-206]

Takano *et al*.[@b60-rado-47-03-206] found that DWI WB-MRI had a higher detection rate of metastatic lesions in 11 patients with paraganglioma when compared with metaiodobenzylguanidine scintigraphy or FDG-PET, particularly for lymph nodal and liver metastases. The limitations of DWI WB-MRI were possible false-positive findings and lower detectability of mediastinal lymph nodes and lung metastases.[@b60-rado-47-03-206]

### General remarks and conclusions

On the basis of our systematic review, we found several articles in which mixed tumour types were evaluated using both imaging methods.[@b17-rado-47-03-206]--[@b28-rado-47-03-206] For what concerns the specific tumour types, more evidence exists for lymphomas[@b29-rado-47-03-206]--[@b35-rado-47-03-206], bone tumours[@b36-rado-47-03-206]--[@b42-rado-47-03-206], head and neck tumours[@b43-rado-47-03-206]--[@b47-rado-47-03-206] and lung tumours[@b48-rado-47-03-206]--[@b51-rado-47-03-206], whereas there is less evidence for other tumour types.

Overall, based on the literature findings, WB-MRI seems to be a valid alternative method compared to PET/CT in oncology. Nevertheless, it should be considered that the studies included in this systematic review were highly heterogeneous not only about the patient population evaluated ([Table 1](#t1-rado-47-03-206){ref-type="table"}), but also for those technical aspects related to PET imaging and WB-MRI ([Table 2](#t2-rado-47-03-206){ref-type="table"}). In particular, DWI, when performed, seemed to provide an added value to WB-MRI compared to FDG-PET/CT, increasing the sensitivity (due to a better lesion to background contrast).

A possible limitation of some studies evaluated in this systematic review is the reference standard used. In fact, in some articles the diagnostic performance of WB-MRI was assessed considering PET or PET/CT as a reference standard. This is a possible source of bias, because FDG-PET or PET/CT has its own limitations, mainly due to the possibility of false-positive or false-negative results, which could affect the diagnostic accuracy calculated for WB-MRI ([Table 3](#t3-rado-47-03-206){ref-type="table"}).

Possible advantages of WB-MRI compared to FDG-PET or PET/CT are: the lack of ionizing radiation, the higher soft-tissue contrast, the higher spatial resolution, the better assessment of non FDG-avid tumour types or sites of physiological FDG uptake. On the other hand, it should be considered that WB-MRI has a longer examination time compared to PET/CT and more variable acquisition protocols.

Both these imaging techniques still show limited worldwide availability if compared to other conventional imaging methods.

Referring to the costs, Plathow *et al*.[@b61-rado-47-03-206], performing a cost-analysis study, demonstrated that both whole-body imaging techniques allow substantial reduction of health care costs in many tumour types. On the basis of a simple full cost analysis, total costs of whole-body PET/CT were higher than those of whole-body MRI by a factor of about 2.0.[@b61-rado-47-03-206]

Further larger prospective studies and in particular cost-effectiveness analysis comparing these two whole-body imaging techniques is needed to better assess the role of WB-MRI compared to FDG-PET or PET/CT in specific tumour types. Furthermore, emerging hybrid PET/MRI devices will increase the number of studies comparing PET to WB-MRI.

![Flow chart of the search for eligible studies on the comparison of FDG-PET or PET/CT and WB-MRI in oncology.](rado-47-03-206f1){#f1-rado-47-03-206}

###### 

Basic studies and patient characteristics

  **Authors**                                  **Year**   **Country**   **Study type**   **No. of patients**   **Mean Age**   **% Male**   **Type of tumors**
  -------------------------------------------- ---------- ------------- ---------------- --------------------- -------------- ------------ -----------------------
  Antoch *et al*.[@b17-rado-47-03-206]         2003       Germany       Prospective      98                    58             64%          Mixed
  Schmidt *et al*.[@b18-rado-47-03-206]        2005       Germany       Prospective      41                    56             44%          Mixed
  Komori *et al.*[@b19-rado-47-03-206]         2007       Japan         NR               16                    66             70%          Mixed
  Li *et al*.[@b20-rado-47-03-206]\[18\]       2007       China         NR               30                    48             37%          Mixed
  Brauck *et al*.[@b21-rado-47-03-206]         2008       Germany       Prospective      11                    53             63%          Mixed
  Yang *et al*.[@b22-rado-47-03-206]           2008       China         NR               56                    57             71%          Mixed
  Stecco *et al*.[@b23-rado-47-03-206]         2009       Italy         Prospective      29                    NR             NR           Mixed
  Krohmer *et al*.[@b24-rado-47-03-206]        2010       Germany       Prospective      24                    11             NR           Mixed
  Fischer *et al*.[@b25-rado-47-03-206]        2011       Switzerland   Prospective      66                    60             66%          Mixed
  Schmidt *et al*.[@b26-rado-47-03-206]        2012       Germany       Retrospective    135                   61             45%          Mixed
  Cafagna *et al*.[@b27-rado-47-03-206]        2012       Italy         Retrospective    38                    60             47%          Mixed
  Manenti *et al*.[@b28-rado-47-03-206]        2012       Italy         Retrospective    45                    66             53%          Mixed
  Punwani *et al*.[@b29-rado-47-03-206]        2010       England       NR               31                    13             58%          Lymphoma
  van Ufford *et al*.[@b30-rado-47-03-206]     2011       Netherlands   Prospective      22                    49             68%          Lymphoma
  Abdulqadhr *et al*.[@b31-rado-47-03-206]     2011       Sweden        Prospective      31                    47             64%          Lymphoma
  Gu *et al*.[@b32-rado-47-03-206]             2011       China         NR               17                    50             65%          Lymphoma
  Lin *et al*.[@b33-rado-47-03-206]            2011       France        Prospective      15                    48             60%          Lymphoma
  Wu *et al*.[@b34-rado-47-03-206]             2011       Finland       Prospective      8                     54             50%          Lymphoma
  Chen *et al*.[@b35-rado-47-03-206]           2012       China         Prospective      10                    45             40%          Lymphoma
  Shortt *et al*.[@b36-rado-47-03-206]         2009       Ireland       NR               24                    67             46%          Multiple Mieloma
  Daldrup-Link *et al*.[@b37-rado-47-03-206]   2001       Germany       NR               39                    13             69%          Bone
  Schmidt *et al*.[@b38-rado-47-03-206]        2007       Germany       Prospective      30                    58             60%          Bone
  Ribrag *et al*.[@b39-rado-47-03-206]         2008       France        Prospective      47                    50             50%          Bone
  Kumar *et al*.[@b40-rado-47-03-206]          2008       India         NR               26                    NR             NR           Bone
  Takenaka *et al*.[@b41-rado-47-03-206]       2009       Japan         Prospective      115                   72             57%          Bone
  Heusner *et al*.[@b42-rado-47-03-206]        2011       Germany       Prospective      109                   57             60%          Bone
  Ng *et al*.[@b43-rado-47-03-206]             2010       Taiwan        Prospective      179                   47             75%          Head and neck
  O'Neill *et al*.[@b44-rado-47-03-206]        2010       Ireland       Prospective      15                    59             66%          Head and neck
  Ng *et al*.[@b45-rado-47-03-206]             2011       Taiwan        Prospective      79                    52             88%          Head and neck
  Chan *et al*.[@b46-rado-47-03-206]           2011       Taiwan        Prospective      103                   53             94%          Head and neck
  Eiber *et al*.[@b47-rado-47-03-206]          2012       Germany       Prospective      20                    56             80%          Head and neck
  Plathow *et al*.[@b48-rado-47-03-206]        2008       Germany       NR               52                    62             69%          Lung
  Ohno *et al*.[@b49-rado-47-03-206]           2008       Japan         Prospective      203                   72             53%          Lung
  Yi *et al*.[@b50-rado-47-03-206]             2008       Korea         Prospective      165                   61             72%          Lung
  Chen *et al*.[@b51-rado-47-03-206]           2010       China         NR               56                    51             62%          Lung
  Pfannenberg *et al*.[@b52-rado-47-03-206]    2007       Germany       Prospective      64                    58             41%          Melanoma
  Laurent *et al*.[@b53-rado-47-03-206]        2010       France        Prospective      35                    NR             NR           Melanoma
  Dellestable *et al*.[@b54-rado-47-03-206]    2011       France        Prospective      40                    57             50%          Melanoma
  Schmidt *et al*.[@b55-rado-47-03-206]        2008       Germany       NR               33                    55             0%           Breast
  Heusner *et al*.[@b56-rado-47-03-206]        2010       Germany       Prospective      20                    54             0%           Breast
  Squillaci *et al*.[@b57-rado-47-03-206]      2008       Italy         NR               20                    56             60%          Colorectal
  Schmidt *et al*.[@b58-rado-47-03-206]        2009       Germany       Retrospective    24                    62             NR           Colorectal
  Giraudet *et al*.[@b59-rado-47-03-206]       2007       France        Prospective      55                    56             62%          Neuroendocrine tumors
  Takano *et al*.[@b60-rado-47-03-206]         2008       Japan         Prospective      11                    40             55%          Neuroendocrine tumors

NR = not reported

###### 

Technical aspects of the included studies

  **Authors**                                  **Device activity**   **Injected**   **Time between tracer injection and image acquisition (min)**   **PET acquisition protocol**                    **Image analysis**                **Field strenght (T)**   **Sequences used**                                                                                                                                                                                                                                               **Slice thickness**   **Contrast media administration**   **DWI**                        **ADC**   **Acquisition time (min)**   **Reference standard**
  -------------------------------------------- --------------------- -------------- --------------------------------------------------------------- ----------------------------------------------- --------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ----------------------------------- ------------------------------ --------- ---------------------------- ---------------------------------------------
  Antoch *et al*.[@b17-rado-47-03-206]         PET/CT                350 MBq        60                                                              Static acquisition (3--5min per bed position)   Qualitative                       1.5                      T1w(chest, abdomen), T2w(chest, abdomen), T1w(chest, abdomen)after CM, T2w(chest, abdomen)after CM                                                                                                                                                               7mm                   Yes                                 No                             No        26                           Histology and/or follow up
  Schmidt *et al*.[@b18-rado-47-03-206]        PET/CT                200 MBq        60                                                              Static acquisition (3min per bed position)      Qualitative, semi-quantitative    1.5                      STIR(WB), HASTE(chest), T1w(WB), 3D-VIBE(abdomen, pelvis)after CM                                                                                                                                                                                                5mm                   Yes                                 No                             No        55                           Histology and PET/CT
  Komori *et al*.[@b19-rado-47-03-206]         PET/CT                3.7 MBq/kg     60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      DW-EPI(WB)                                                                                                                                                                                                                                                       6mm                   No                                  Yes (Bvalue0-1000mm2/s)        Yes       9                            Histology and/or follow up
  Li *et al*.[@b20-rado-47-03-206]             PET                   NR             NR                                                              Static aquisition                               Qualitative, semi-quantitative    1.5                      DW-EPI-STIR(WB)                                                                                                                                                                                                                                                  7mm                   No                                  Yes (Bvalue0-800mm2/s)         Yes       30                           Follow up
  Brauck *et al*.[@b21-rado-47-03-206]         PET/CT                300--340 MBq   60                                                              Static aquisition                               Qualitative                       1.5                      T1wSSFP(WB), T1wSSFP(WB) after CM, T2wSSFP(WB)                                                                                                                                                                                                                   5mm                   Yes                                 No                             No        6                            PET/CT
  Yang *et al*.[@b22-rado-47-03-206]           PET                   NR             NR                                                              Static acquisition                              Qualitative                       1.5                      DW-EPI-STIR(WB)                                                                                                                                                                                                                                                  7mm                   No                                  Yes (Bvalue0-400-600mm2/s)     No        17--21                       Follow up
  Stecco *et al*.[@b23-rado-47-03-206]         PET/CT                3.5 MBq/kg     60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      DW-EPI-STIR(WB)                                                                                                                                                                                                                                                  5mm                   No                                  Yes (Bvalue0-500-1000mm2/s)    No        20                           PET/CT
  Krohmer *et al*.[@b24-rado-47-03-206]        PET                   NR             NR                                                              Static aquisition                               Qualitative                       1.5                      T2w-STIR(WB), T1wTSE(WB)                                                                                                                                                                                                                                         6--8mm                No                                  No                             No        45                           Follow up
  Fischer *et al*.[@b25-rado-47-03-206]        PET/CT                350 MBq        60                                                              Static acquisition                              Qualitative                       1.5                      DW-EPI-FS(WB), T2wFIESTA(WB)                                                                                                                                                                                                                                     7mm                   No                                  Yes (Bvalue0-700mm2/s)         Yes       40                           PET/CT
  Schmidt *et al*.[@b26-rado-47-03-206]        PET/CT                294 MBq        60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      STIR(WB), HASTE(abdomen), HASTE(lung), STIR-lung, T2w-FS-TSE(liver), T1wTSE(WB), T1wTSE(spine), STIR(spine), VIBE(liver), T1-FS- GE(pelvis), T1wTSE(brain), T2wTSE(brain)                                                                                        3--5mm                Yes                                 No                             No        51                           Follow up
  Cafagna *et al*.[@b27-rado-47-03-206]        PET/CT                370--550 MBq   60                                                              Static acquisition (3min per bed position)      Qualitative, semi- quantitative   1.5                      TSE(WB), DW-EPI-STIR(WB)                                                                                                                                                                                                                                         5mm                   No                                  Yes (B-value0-500-1000mm2/s)   Yes       51                           Follow up
  Manenti *et al*.[@b28-rado-47-03-206]        PET/CT                NR             NR                                                              Static acquisition (4min per bed position)      Qualitative                       3.0                      T1wTFE(WB), T2wTFE(WB), THRIVE- FFE(WB), DW-EPI-STIR(WB)                                                                                                                                                                                                         4--6mm                Yes                                 Yes (B-value0-1000mm2/s)       No        35                           Histology and/or follow up
  Punwani *et al*.[@b29-rado-47-03-206]        PET/CT                370 MBq        60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      STIR-RARE(WB)                                                                                                                                                                                                                                                    7mm                   No                                  No                             No        25--30                       PET/CT
  van Ufford *et al*.[@b30-rado-47-03-206]     PET/CT                3 MBq/kg       60                                                              Static acquisition (3min per bed position)      Qualitative                       1.5                      T1wTSE(WB), T1wSTIR(WB), DW-EPI(head, neck), DW-EPI-FS(chest, abdomen, pelvis)                                                                                                                                                                                   6mm                   No                                  Yes (Bvalue0-1000mm2/s)        No        55                           Follow up
  Abdulqadhr *et al*.[@b31-rado-47-03-206]     PET/CT                5 MBq/kg       60                                                              Static acquisition (3min per bed position)      Qualitative                       1.5                      T1wTSE(WB), T2wSTIR- FS, DWIBS(WB), T2wTSE, T1wGE(chest, abdomen)                                                                                                                                                                                                6mm                   No                                  Yes (Bvalue0-1000mm2/s)        No        50                           Histology and/or follow up
  Gu *et al*.[@b32-rado-47-03-206]             PET/CT                4.8 MBq/kg     60                                                              Static acquisition (4min per bed position)      Qualitative                       3.0                      T2wSPAIR-FS, DW-EPI-STIR                                                                                                                                                                                                                                         5mm                   No                                  Yes (B-value0-1000mm2/sec)     No        48                           PET/CT
  Lin *et al*.[@b33-rado-47-03-206]            PET/CT                5 MBq/kg       60                                                              Static acquisition (2min per bed position)      Qualitative, semi-quantitative    1.5                      DW-EPI-FS(WB)                                                                                                                                                                                                                                                    5mm                   No                                  Yes (Bvalue50-400-800mm2/s)    Yes       30--45                       PET/CT
  Wu *et al*.[@b34-rado-47-03-206]             PET/CT                370 MBq        60                                                              Static acquisition (3min per bed position)      Qualitative, semi-quantitative    3.0                      T1wTSE(WB), T2wIR(WB), T1wGEVIBE(neck, abdomen), T1wGE-VIBE(neck, abdomen)after CM, T2wTSE(neck, abdomen), T2wTSE-FS(abdomen), DW-EPI(WB)                                                                                                                        1--5mm                Yes                                 Yes (Bvalue0-800mm2/s)         Yes       27                           Follow up
  Chen *et al*.[@b35-rado-47-03-206]           PET and PET/CT        NR             NR                                                              NR                                              NR                                1.5                      DW-EPI-STIR, FSE                                                                                                                                                                                                                                                 6--7mm                No                                  Yes (B-value0-800mm2/s)        Yes       43                           Histology
  Shortt *et al*.[@b36-rado-47-03-206]         PET/CT                250--440 MBq   90                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      STIR(WB), T1wTSE(WB)                                                                                                                                                                                                                                             8mm                   No                                  No                             No        20                           Histology
  Daldrup-Link *et al*.[@b37-rado-47-03-206]   PET                   3.7 MBq/kg     60                                                              Static acquisition (4-6min per bed position)    Qualitative                       1.5                      T1wSE, T2wSTIR-FS                                                                                                                                                                                                                                                4--6mm                No                                  No                             No        45--60                       Histology and/or follow up
  Schmidt *et al*.[@b38-rado-47-03-206]        PET/CT                202--372 MBq   60                                                              Static acquisition (3min per bed position)      Qualitative, semi-quantitative    1.5                      STIR(WB), HASTE-STIR(lung), T2wSE(liver), T1wSE(WB), T1w+STIR(spine), 3D-VIBE(liver)after CM, T1wGE-FS(abdomen)after CM, T1w+T2w(skull)                                                                                                                          5mm                   Yes                                 No                             No        55                           Histology and/or follow up
  Ribrag *et al*.[@b39-rado-47-03-206]         PET/CT                539 MBq        46--184                                                         Static acquisition (7--8min per bed position)   Qualitative, semi-quantitative    1.5                      STIR(WB), T1wSE(WB)                                                                                                                                                                                                                                              8mm                   No                                  No                             No        20                           Histology
  Kumar *et al*.[@b40-rado-47-03-206]          PET/CT                5.2 MBq/kg     45                                                              Static acquisition                              Qualitative                       1.5                      SE-STIR(WB)                                                                                                                                                                                                                                                      NR                    No                                  No                             No        40--60                       Histology and/or follow up
  Takenaka *et al*.[@b41-rado-47-03-206]       PET/CT                3.3 MBq/kg     60                                                              Static acquisition (2min per bed position)      Qualitative, semi-quantitative    1.5                      T1wGE(WB), T1wGE(WB)after CM, Opposed-phase T1 GE(WB), STIR- TSE(WB), DW-EPI-STIR(WB)                                                                                                                                                                            8mm                   Yes                                 Yes (Bvalue0-1000mm2/s)        No        75                           Follow up
  Heusner *et al*.[@b42-rado-47-03-206]        PET/CT                260 MBq        60                                                              Static acquisition (4--6min per bed position)   Qualitative, semi-quantitative    1.5                      T1wGE(chest, abdomen), T2wHASTE(chest, abdomen), T1wVIBE(abdomen)after CM, T1wVIBE(head, chest pelvis) after CM                                                                                                                                                  3--7mm                Yes                                 No                             No        NR                           Follow up
  Ng *et al*.[@b43-rado-47-03-206]             PET/CT                370 MBq        50--70                                                          Static acquisition (3min per bed position)      Qualitative                       3.0                      T2wTSE-FS(head, neck, T1wTSE(head, neck), T1wTSE(spine), STIR(spine)T1wTSE-WB, STIR-WB, T2wHASTE(chest, abdomen), T1wVIBE(abdomen), T1wVIBE(abdomen in artery, portal, equilibrium phase) after CM, T1wVIBE(chest, pelvis) after CM, T1wTSE-FS after CM          3--5mm                Yes                                 No                             No        37                           Histology and/or follow up
  O'Neill *et al*.[@b44-rado-47-03-206]        PET/CT                NR             NR                                                              NR                                              Qualitative                       1.5                      NR                                                                                                                                                                                                                                                               NR                    NR                                  No                             No        20                           NR
  Ng *et al*.[@b45-rado-47-03-206]             PET/CT                370 MBq        50--70                                                          Static acquisition (3min per bed position)      Qualitative                       3.0                      T2wTSE-FS(head, neck), T1wTSE(head, neck), T1wTSE(spine), STIR(spine), T1wTSE(WB), STIR(WB), T2wHASTE(chest, abdomen), T1wVIBE(abdomen), T1wVIBE(abdomen)after CM, T1wVIBE(chest, pelvis)after CM, T1wTSE-FS after CM                                            3--5mm                Yes                                 No                             No        37                           Histology and/or follow up
  Chan *et al*.[@b46-rado-47-03-206]           PET/CT                370 MBq        50--70                                                          Static acquisition (2min per bed position)      Qualitative, semi-quantitative    3.0                      T2wTSE-FS(head, neck), T1wTSE(head, neck), T1wTSE(spine), STIR(spine)T1wTSE(WB), STIR(WB), T2wHASTE(chest, liver), T1wVIBE(abdomen), T1wVIBE(abdomen)after CM, T1wVIBE(chest, pelvis)after CM, T1wTSE-FS after CM                                                3--5mm                Yes                                 No                             No        50                           Histology and/or follow up
  Eiber *et al*.[@b47-rado-47-03-206]          PET/CT                350--500 MBq   90                                                              Static acquisition (2min per bed position)      Qualitative                       3.0                      Dixon VIBE T1w(WB), T2 STIR(neck), T1 TSE(neck), T1 TSE after CM(neck), T1 TSE FS after CM(neck), VIBE T1w dynamic(liver), VIBE T1w after CM(lungs)                                                                                                              2.6--5mm              Yes                                 No                             No        23                           Histology and/or follow up
  Plathow *et al*.[@b48-rado-47-03-206]        PET/CT                360--400 MBq   55--65                                                          Static acquisition (3min per bed position)      Qualitative                       1.5                      STIR(chest), VIBE-FS                                                                                                                                                                                                                                             NR                    NR                                  No                             No        60                           Histology and/or follow up
  Ohno *et al*.[@b49-rado-47-03-206]           PET/CT                3.3 MBq/kg     60                                                              Static acquisition (2min per bed position)      Qualitative                       1.5                      T1wGE(WB), T1wGE(WB)after CM, Opposed-phase T1wGE(WB), STIR-TSE(WB, DW-EPI-STIR(WB)                                                                                                                                                                              NR                    Yes                                 Yes (Bvalue0-1000mm2/s)        No        75                           Histology and/or follow up
  Yi *et al*.[@b50-rado-47-03-206]             PET/CT                370 MBq        45                                                              Static acquisition                              Qualitative                       3.0                      T2wTSE-FS(WB), T1wTFE(WB) after CM                                                                                                                                                                                                                               4--8mm                Yes                                 No                             No        40                           Histology and/or follow up
  Chen *et al*.[@b51-rado-47-03-206]           PET/CT                3.3 MBq/kg     60                                                              Static acquisition                              Qualitative                       1.5                      DW-EPI(WB)                                                                                                                                                                                                                                                       6mm                   No                                  Yes (Bvalue0-1000mm2/s)        No        12                           Histology and/or follow up
  Pfannenberg *et al*.[@b52-rado-47-03-206]    PET/CT                370 MBq        55--65                                                          Static acquisition (3min per bed position)      Qualitative, semi-quantitative    1.5                      NR                                                                                                                                                                                                                                                               NR                    NR                                  No                             No        NR                           Histology and/or follow up
  Laurent *et al*.[@b53-rado-47-03-206]        PET/CT                5.5 MBq/kg     60                                                              Static acquisition (3--4 min per bed position   Qualitative                       1.5                      2D-STIR(WB), 3D-T1w(WB)after CM, DW-EPI(WB)                                                                                                                                                                                                                      7--8mm                Yes                                 Yes (Bvalue0-600mm2/s)         No        60                           Histology and/or follow up
  Dellestable *et al*.[@b54-rado-47-03-206]    PET/CT                5.5 MBq/kg     60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      T2wSTIR(WB), T1(WB), DWI(WB), T1w3D-GE(WB)after CM                                                                                                                                                                                                               NR                    Yes                                 Yes (Bvalue NR)                No        60                           Histology and/or follow up
  Schmidt *et al*.[@b55-rado-47-03-206]        PET/CT                200 MBq        60                                                              Static acqusition                               Qualitative, semi-quantitative    1.5--3.0                 STIR(WB), HASTE(abdomen), HASTE(lung), STIR(lung), T2w-SE FS(liver), T1wTSE(WB), T1wTSE(spine), STIR(spine), Dyn. VIBE(liver)after CM, Static VIBE(lung, breast)after CM, T1wGE- FS(pelvis)after CM, T1wSE(brain) after CM, T1wGE(brain), T2wSE(brain)after CM   NR                    Yes                                 No                             No        43--52                       Histology and/or follow up
  Heusner *et al*.[@b56-rado-47-03-206]        PET/CT                300 MBq        60                                                              Static acquisition(4min per bed position)       Qualitative, semi-quantitative    1.5                      DW-EPI(WB), HASTE-FS(spine), DW-EPI(spine), T2wSPAIR(WB), T1wFLASH(WB), T2wHASTE(WB), T1wVIBE(WB)after CM                                                                                                                                                        3--6mm                Yes                                 Yes (Bvalue50-600-800mm2/s)    Yes       NR                           Histology and/or follow up
  Squillaci *et al*.[@b57-rado-47-03-206]      PET/CT                370 MBq        45--60                                                          Static acquisition (4min per bed position)      Qualitative, semi-quantitative    3.0                      T1wFFE(WB), T2wTSE(WB), T2wTSE- STIR(WB), THRIVE-SPAIR(WB), T1wFFE(WB)after CM                                                                                                                                                                                   4--6mm                Yes                                 No                             No        47--55                       Histology and/or clinical/imaging follow up
  Schmidt *et al*.[@b58-rado-47-03-206]        PET/CT                197--390 MBq   60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5--3.0                 STIR(WB), T1wTSE(WB), HASTE(lung), STIR(lung), T2wTSE-FS(liver), STIR(spine), T1wTSE(spine), VIBE(liver)after CM, T1wTSE(brain) after CM, T2wTSE(brain)after CM, T1wGE-FS(abdomen)after CM                                                                       1.5--6mm              Yes                                 No                             No        42--51                       Follow up
  Giraudet *et al*.[@b59-rado-47-03-206]       PET/CT                5 MBq/kg       60                                                              Static acquisition                              Qualitative, semi-quantitative    1.5                      T2wFSE(liver), dynamic contrast-enhanced MRI, T1-weighted sequences with fast multiplanar spoiled gradient-recalled echo imaging, STIR(WB), T1wSE(WB)                                                                                                            7mm                   No                                  No                             No        NR                           Follow up
  Takano *et al*.[@b60-rado-47-03-206]         PET                   5 MBq/kg       50                                                              Static acquisition (8min per bed position)      Qualitative                       1.5                      T1wGE(WB), T2wFSE(WB), DW-EPI-STIR(WB)                                                                                                                                                                                                                           4mm                   No                                  Yes (Bvalue 0-1000mm2/s)       No        NR                           Histology and/or follow up

NR = not reported; CM = contrast media; DWIBS = diffusion weighted imaging with background body signal suppression; WB = whole-body

###### 

Diagnostic performance of PET and WB-MRI in the included studies

  Authors                                      Sensitivity (%)                          Specificity (%)                     Accuracy(%)                                                                                                                                                                                                                                                                                   
  -------------------------------------------- ---------------------------------------- ----------------------------------- ----------------------------------------- ----------------------------------- ------------------------------------------ ---------------------------- ----------------------------------------- ---------------------------- --------- ----------------------------- ------------------------ ---------------------------
  Antoch *et al*.[@b17-rado-47-03-206]         NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Schmidt *et al*.[@b18-rado-47-03-206]        NR                                       RS                                  NR                                        89                                  NR                                         RS                           NR                                        86                           NR        RS                            NR                       88
  Komori *et al*.[@b19-rado-47-03-206]         NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Li *et al*.[@b20-rado-47-03-206]             NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Brauck *et al*.[@b21-rado-47-03-206]         NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Yang *et al*.[@b22-rado-47-03-206]           NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Stecco *et al*.[@b23-rado-47-03-206]         NR                                       RS                                  NR                                        87--89                              NR                                         RS                           NR                                        98--99                       NR        RS                            NR                       97--99
  Krohmer *et al*.[@b24-rado-47-03-206]        NR                                       RS                                  NR                                        96                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Fischer *et al*.[@b25-rado-47-03-206]        RS                                       RS                                  85(WB-MRI), 88(DWI)                       57(WB-MRI), 64(DWI)                 RS                                         NR                           81(WB-MRI), 69(DWI)                       NR                           RS        NR                            84(WB-MRI), 83(DWI)      NR
  Schmidt *et al*.[@b26-rado-47-03-206]        94                                       NR                                  91                                        NR                                  97                                         NR                           88                                        NR                           96        NR                            89                       NR
  Cafagna *et al*.[@b27-rado-47-03-206]        NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Manenti *et al*.[@b28-rado-47-03-206]        NR                                       RS                                  NR                                        96(WB-MRI), 94(DWI)                 NR                                         RS                           NR                                        100(WB-MRI), 100(DWI)        NR        RS                            NR                       97(WB-MRI), 96(DWI)
  Punwani *et al*.[@b29-rado-47-03-206]        NR                                       100 (nodal) 96(extranodal)          NR                                        98(nodal) 91(extranodal)            NR                                         100(nodal) 100(extranodal)   NR                                        99 (nodal) 99 (extranodal)   NR        100 (nodal) 100(extranodal)   NR                       99 (nodal) 99(extranodal)
  van Ufford *et al*.[@b30-rado-47-03-206]     NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Abdulqadhr *et al*.[@b31-rado-47-03-206]     NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Gu *et al*.[@b32-rado-47-03-206]             NR                                       RS                                  NR                                        89(WB-MRI), 97(DWI)                 NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Lin *et al*.[@b33-rado-47-03-206]            NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Wu *et al*.[@b34-rado-47-03-206]             NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Chen *et al*.[@b35-rado-47-03-206]           NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Shortt *et al*.[@b36-rado-47-03-206]         NR                                       59                                  NR                                        68                                  NR                                         75                           NR                                        83                           NR        65                            NR                       74
  Daldrup-Link *et al*.[@b37-rado-47-03-206]   86                                       90                                  76                                        82                                  89                                         NR                           100                                       NR                           87        NR                            87                       NR
  Schmidt *et al*.[@b38-rado-47-03-206]        NR                                       98(N-stage), 82(M-stage)            NR                                        80(N-stage), 96(M-stage)            NR                                         83(N-stage), 82(M-stage)     NR                                        75(N-stage), 82(M-stage)     NR        96(TNM)                       NR                       91(TNM)
  Ribrag *et al*.[@b39-rado-47-03-206]         100(bone lesions), 29 (bone marrow)      96(bone lesions), 95(bone marrow)   100(bone lesions), 100(bone marrow)       83(bone lesions), 90(bone marrow)   NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Kumar *et al*.[@b40-rado-47-03-206]          NR                                       90                                  NR                                        97                                  NR                                         100                          NR                                        99                           NR        98                            NR                       99
  Takenaka *et al*.[@b41-rado-47-03-206]       96                                       97                                  64(WB-MRI), 96(DWI)                       73(WB-MRI), 95(DWI)                 86                                         95                           90(WB-MRI) 79(DWI)                        96(WB-MRI), 94(DWI)          88        95                            84(WB-MRI), 83(DWI)      95(WB-MRI), 94(DWI)
  Heusner *et al*.[@b42-rado-47-03-206]        45                                       NR                                  64                                        NR                                  99                                         NR                           94                                        NR                           94        NR                            91                       NR
  Ng *et al*.[@b43-rado-47-03-206]             87                                       87                                  91                                        89                                  90                                         96                           91                                        97                           89        95                            91                       96
  O'Neill *et al*.[@b44-rado-47-03-206]        NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Ng *et al*.[@b45-rado-47-03-206]             72                                       71                                  55                                        64                                  94                                         96                           90                                        96                           86        92                            76                       91
  Chan *et al*.[@b46-rado-47-03-206]           NR                                       81                                  NR                                        62                                  NR                                         99                           NR                                        99                           NR        99                            NR                       98
  Eiber *et al*.[@b47-rado-47-03-206]          NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Plathow *et al*.[@b48-rado-47-03-206]        92(T-stage), 96(N-stage), 100(M-stage)   NR                                  100(T-stage), 88(N-stage), 100(M-stage)   NR                                  100(T-stage), 100(N-stage), 100(M-stage)   NR                           100(T-stage), 96(N-stage), 100(M-stage)   NR                           NR        NR                            NR                       NR
  Ohno *et al*.[@b49-rado-47-03-206]           62--70                                   NR                                  56--60(WB-MRI), 57--67(DWI)               NR                                  94                                         NR                           92(WB-MRI), 88(DWI)                       NR                           88--90    NR                            86(WB-MRI), 82-84(DWI)   NR
  Yi *et al*.[@b50-rado-47-03-206]             48                                       NR                                  52                                        NR                                  96                                         NR                           94                                        NR                           86        NR                            86                       NR
  Chen *et al*.[@b51-rado-47-03-206]           NR                                       98                                  NR                                        91                                  NR                                         98                           NR                                        92                           NR        97                            NR                       91
  Pfannenberg *et al*.[@b52-rado-47-03-206]    NR                                       90                                  NR                                        80                                  NR                                         77                           NR                                        76                           NR        87                            NR                       79
  Laurent *et al*.[@b53-rado-47-03-206]        NR                                       73                                  NR                                        83                                  NR                                         93                           NR                                        98                           NR        NR                            NR                       NR
  Dellestable *et al*.[@b54-rado-47-03-206]    NR                                       74                                  NR                                        83                                  NR                                         89                           NR                                        96                           NR        74                            NR                       81
  Schmidt *et al*.[@b55-rado-47-03-206]        NR                                       91                                  NR                                        90                                  NR                                         90                           NR                                        86                           NR        91                            NR                       91
  Heusner *et al*.[@b56-rado-47-03-206]        75--100                                  94                                  66--100                                   91                                  94--100                                    99                           0--100                                    72                           93--100   98                            30--100                  76
  Squillaci *et al*.[@b57-rado-47-03-206]      NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Schmidt *et al*.[@b58-rado-47-03-206]        NR                                       86                                  NR                                        72                                  NR                                         96                           NR                                        93                           NR        91                            NR                       83
  Giraudet *et al*.[@b59-rado-47-03-206]       NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR
  Takano *et al*.[@b60-rado-47-03-206]         NR                                       NR                                  NR                                        NR                                  NR                                         NR                           NR                                        NR                           NR        NR                            NR                       NR

NR = not reported; Pt = per patient-based analysis; Les = per lesion-based analysis; DWI = diffusion weighted imaging; WB-MRI = whole body magnetic resonance imaging
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